stainless steel screens (2-µm pores) Search Results


silver membrane filter  (Sterlitech corporation)
95
Sterlitech corporation silver membrane filter
Silver Membrane Filter, supplied by Sterlitech corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/Sterlitech+Silver+Membrane/10__5194_slash_acp___15___13569___2015-84-5-12
Average 95 stars, based on 1 article reviews
silver membrane filter - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
microforge  (Narishige inc)
96
Narishige inc microforge
Microforge, supplied by Narishige inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/End+cap+with+stainless+steel+collar+for+%C3%B81%2E2mm+tube/ppr0713537-149-14-17
Average 96 stars, based on 1 article reviews
microforge - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
cip particles  (BASF)
90
BASF cip particles
Cip Particles, supplied by BASF, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/cip+cc/ppr0904905-158-9-6
Average 90 stars, based on 1 article reviews
cip particles - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
supernatants sfca  (Corning Life Sciences)
90
Corning Life Sciences supernatants sfca
Supernatants Sfca, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/low+protein+binding+filter/pmc07606601-166-2-5
Average 90 stars, based on 1 article reviews
supernatants sfca - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
tem grids hole, gap  (QUANTIFOIL gmbh)
90
QUANTIFOIL gmbh tem grids hole, gap
Tem Grids Hole, Gap, supplied by QUANTIFOIL gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/tem+grids+hole++gap/pm31437582-76-20-22
Average 90 stars, based on 1 article reviews
tem grids hole, gap - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
sb431542  (ApexBio)
90
ApexBio sb431542
Sb431542, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/sb431542/pmc10202391-220-50-54
Average 90 stars, based on 1 article reviews
sb431542 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
purmorphamine  (FUJIFILM)
90
FUJIFILM purmorphamine
Purmorphamine, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/purmorphamine/bio_rxiv__2022__04__29__489839-202-14-15
Average 90 stars, based on 1 article reviews
purmorphamine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
thz1  (Xcessbio Inc)
90
Xcessbio Inc thz1
(A) Left panel: Schematic of the genomic locus of CSB and used strategy for generating the homozygous CSB-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for CSB -KI cell line. (B) Left panel: Schematic of the genomic locus of UVSSA and used strategy for generating the homozygous UVSSA-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for UVSSA -KI cell line. (C) Left panel: CSB mobility was determined by FRAP analysis of CSB-mScarletI after the indicated treatments. <t>THZ1:</t> 1 hour treatment (2 µM) before UV-C irradiation (4 J/m 2 ) or mock treatment. Right panel: Relative immobile fraction of CSB as determined by FRAP analysis. Plotted values represent mean ± SEM and are normalized to mock treated. n≥15 cells. (D) Same as C but for UVSSA-mScarletI. n≥10 cells. (E+F) FRAP analyses of CSB-mScarletI (E) or UVSSA-mScarletI (F) mobility after transfection with indicated siRNAs in individual graphs. Cells were mock treated (NT) or analyzed directly (UV) or 5 hours (5hr UV) after irradiation with 4 J/m 2 UV-C. (G) Relative fluorescence intensity of UVSSA in UVSSA -KI cells transfected with indicated siRNAs as determined by live-cell imaging. Plotted values represent mean ± SEM. n≥16 cells. (H) FRAP analysis of CSB in CSB -KI cells transfected with indicated siRNAs 2 hours after UV. VCPi: VCP inhibitor (5 µM) was directly added after UV-C (4 J/m 2 ). (I) Immunoblot of chromatin fraction of indicated cell lines 1 hour after 12 J/m 2 UV-C or mock treatment. NAEi = 1 hour treatment with NEDDylation inhibitor (10 µM). SSRP1 is shown as loading control. (J) Immunoblot of chromatin fraction of HCT116 cells transfected with indicated siRNAs 1 hour after 12 J/m 2 UV-C or mock treatment. SSRP1 is shown as loading control.
Thz1, supplied by Xcessbio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/thz1/bio_rxiv__2021__05__11__443558-244-19-20
Average 90 stars, based on 1 article reviews
thz1 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ccd camera  (QImaging)
90
QImaging ccd camera
(A) Left panel: Schematic of the genomic locus of CSB and used strategy for generating the homozygous CSB-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for CSB -KI cell line. (B) Left panel: Schematic of the genomic locus of UVSSA and used strategy for generating the homozygous UVSSA-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for UVSSA -KI cell line. (C) Left panel: CSB mobility was determined by FRAP analysis of CSB-mScarletI after the indicated treatments. <t>THZ1:</t> 1 hour treatment (2 µM) before UV-C irradiation (4 J/m 2 ) or mock treatment. Right panel: Relative immobile fraction of CSB as determined by FRAP analysis. Plotted values represent mean ± SEM and are normalized to mock treated. n≥15 cells. (D) Same as C but for UVSSA-mScarletI. n≥10 cells. (E+F) FRAP analyses of CSB-mScarletI (E) or UVSSA-mScarletI (F) mobility after transfection with indicated siRNAs in individual graphs. Cells were mock treated (NT) or analyzed directly (UV) or 5 hours (5hr UV) after irradiation with 4 J/m 2 UV-C. (G) Relative fluorescence intensity of UVSSA in UVSSA -KI cells transfected with indicated siRNAs as determined by live-cell imaging. Plotted values represent mean ± SEM. n≥16 cells. (H) FRAP analysis of CSB in CSB -KI cells transfected with indicated siRNAs 2 hours after UV. VCPi: VCP inhibitor (5 µM) was directly added after UV-C (4 J/m 2 ). (I) Immunoblot of chromatin fraction of indicated cell lines 1 hour after 12 J/m 2 UV-C or mock treatment. NAEi = 1 hour treatment with NEDDylation inhibitor (10 µM). SSRP1 is shown as loading control. (J) Immunoblot of chromatin fraction of HCT116 cells transfected with indicated siRNAs 1 hour after 12 J/m 2 UV-C or mock treatment. SSRP1 is shown as loading control.
Ccd Camera, supplied by QImaging, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/ccd+camera/pmc03252314-50-9-12
Average 90 stars, based on 1 article reviews
ccd camera - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
golgistop  (Becton Dickinson)
90
Becton Dickinson golgistop
(A) Left panel: Schematic of the genomic locus of CSB and used strategy for generating the homozygous CSB-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for CSB -KI cell line. (B) Left panel: Schematic of the genomic locus of UVSSA and used strategy for generating the homozygous UVSSA-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for UVSSA -KI cell line. (C) Left panel: CSB mobility was determined by FRAP analysis of CSB-mScarletI after the indicated treatments. <t>THZ1:</t> 1 hour treatment (2 µM) before UV-C irradiation (4 J/m 2 ) or mock treatment. Right panel: Relative immobile fraction of CSB as determined by FRAP analysis. Plotted values represent mean ± SEM and are normalized to mock treated. n≥15 cells. (D) Same as C but for UVSSA-mScarletI. n≥10 cells. (E+F) FRAP analyses of CSB-mScarletI (E) or UVSSA-mScarletI (F) mobility after transfection with indicated siRNAs in individual graphs. Cells were mock treated (NT) or analyzed directly (UV) or 5 hours (5hr UV) after irradiation with 4 J/m 2 UV-C. (G) Relative fluorescence intensity of UVSSA in UVSSA -KI cells transfected with indicated siRNAs as determined by live-cell imaging. Plotted values represent mean ± SEM. n≥16 cells. (H) FRAP analysis of CSB in CSB -KI cells transfected with indicated siRNAs 2 hours after UV. VCPi: VCP inhibitor (5 µM) was directly added after UV-C (4 J/m 2 ). (I) Immunoblot of chromatin fraction of indicated cell lines 1 hour after 12 J/m 2 UV-C or mock treatment. NAEi = 1 hour treatment with NEDDylation inhibitor (10 µM). SSRP1 is shown as loading control. (J) Immunoblot of chromatin fraction of HCT116 cells transfected with indicated siRNAs 1 hour after 12 J/m 2 UV-C or mock treatment. SSRP1 is shown as loading control.
Golgistop, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/golgistop/pmc04274804__supp_db13___1639_DB131639SupplementaryData-45-22-25
Average 90 stars, based on 1 article reviews
golgistop - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cim r-protein g lld monolithic 96-well plate ( channels)  (BIA Separations)
90
BIA Separations cim r-protein g lld monolithic 96-well plate ( channels)
(A) Left panel: Schematic of the genomic locus of CSB and used strategy for generating the homozygous CSB-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for CSB -KI cell line. (B) Left panel: Schematic of the genomic locus of UVSSA and used strategy for generating the homozygous UVSSA-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for UVSSA -KI cell line. (C) Left panel: CSB mobility was determined by FRAP analysis of CSB-mScarletI after the indicated treatments. <t>THZ1:</t> 1 hour treatment (2 µM) before UV-C irradiation (4 J/m 2 ) or mock treatment. Right panel: Relative immobile fraction of CSB as determined by FRAP analysis. Plotted values represent mean ± SEM and are normalized to mock treated. n≥15 cells. (D) Same as C but for UVSSA-mScarletI. n≥10 cells. (E+F) FRAP analyses of CSB-mScarletI (E) or UVSSA-mScarletI (F) mobility after transfection with indicated siRNAs in individual graphs. Cells were mock treated (NT) or analyzed directly (UV) or 5 hours (5hr UV) after irradiation with 4 J/m 2 UV-C. (G) Relative fluorescence intensity of UVSSA in UVSSA -KI cells transfected with indicated siRNAs as determined by live-cell imaging. Plotted values represent mean ± SEM. n≥16 cells. (H) FRAP analysis of CSB in CSB -KI cells transfected with indicated siRNAs 2 hours after UV. VCPi: VCP inhibitor (5 µM) was directly added after UV-C (4 J/m 2 ). (I) Immunoblot of chromatin fraction of indicated cell lines 1 hour after 12 J/m 2 UV-C or mock treatment. NAEi = 1 hour treatment with NEDDylation inhibitor (10 µM). SSRP1 is shown as loading control. (J) Immunoblot of chromatin fraction of HCT116 cells transfected with indicated siRNAs 1 hour after 12 J/m 2 UV-C or mock treatment. SSRP1 is shown as loading control.
Cim R Protein G Lld Monolithic 96 Well Plate ( Channels), supplied by BIA Separations, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/cim++r+protein+g+lld+monolithic+96+well+plate+++channels+/pmc11432235-155-17-21
Average 90 stars, based on 1 article reviews
cim r-protein g lld monolithic 96-well plate ( channels) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
purmorphamine  (Merck KGaA)
90
Merck KGaA purmorphamine
(A) Left panel: Schematic of the genomic locus of CSB and used strategy for generating the homozygous CSB-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for CSB -KI cell line. (B) Left panel: Schematic of the genomic locus of UVSSA and used strategy for generating the homozygous UVSSA-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for UVSSA -KI cell line. (C) Left panel: CSB mobility was determined by FRAP analysis of CSB-mScarletI after the indicated treatments. <t>THZ1:</t> 1 hour treatment (2 µM) before UV-C irradiation (4 J/m 2 ) or mock treatment. Right panel: Relative immobile fraction of CSB as determined by FRAP analysis. Plotted values represent mean ± SEM and are normalized to mock treated. n≥15 cells. (D) Same as C but for UVSSA-mScarletI. n≥10 cells. (E+F) FRAP analyses of CSB-mScarletI (E) or UVSSA-mScarletI (F) mobility after transfection with indicated siRNAs in individual graphs. Cells were mock treated (NT) or analyzed directly (UV) or 5 hours (5hr UV) after irradiation with 4 J/m 2 UV-C. (G) Relative fluorescence intensity of UVSSA in UVSSA -KI cells transfected with indicated siRNAs as determined by live-cell imaging. Plotted values represent mean ± SEM. n≥16 cells. (H) FRAP analysis of CSB in CSB -KI cells transfected with indicated siRNAs 2 hours after UV. VCPi: VCP inhibitor (5 µM) was directly added after UV-C (4 J/m 2 ). (I) Immunoblot of chromatin fraction of indicated cell lines 1 hour after 12 J/m 2 UV-C or mock treatment. NAEi = 1 hour treatment with NEDDylation inhibitor (10 µM). SSRP1 is shown as loading control. (J) Immunoblot of chromatin fraction of HCT116 cells transfected with indicated siRNAs 1 hour after 12 J/m 2 UV-C or mock treatment. SSRP1 is shown as loading control.
Purmorphamine, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stainless+steel+screens+(2-%C2%B5m+pores)/purmorphamine/pm38594264-299-89-91
Average 90 stars, based on 1 article reviews
purmorphamine - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


(A) Left panel: Schematic of the genomic locus of CSB and used strategy for generating the homozygous CSB-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for CSB -KI cell line. (B) Left panel: Schematic of the genomic locus of UVSSA and used strategy for generating the homozygous UVSSA-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for UVSSA -KI cell line. (C) Left panel: CSB mobility was determined by FRAP analysis of CSB-mScarletI after the indicated treatments. THZ1: 1 hour treatment (2 µM) before UV-C irradiation (4 J/m 2 ) or mock treatment. Right panel: Relative immobile fraction of CSB as determined by FRAP analysis. Plotted values represent mean ± SEM and are normalized to mock treated. n≥15 cells. (D) Same as C but for UVSSA-mScarletI. n≥10 cells. (E+F) FRAP analyses of CSB-mScarletI (E) or UVSSA-mScarletI (F) mobility after transfection with indicated siRNAs in individual graphs. Cells were mock treated (NT) or analyzed directly (UV) or 5 hours (5hr UV) after irradiation with 4 J/m 2 UV-C. (G) Relative fluorescence intensity of UVSSA in UVSSA -KI cells transfected with indicated siRNAs as determined by live-cell imaging. Plotted values represent mean ± SEM. n≥16 cells. (H) FRAP analysis of CSB in CSB -KI cells transfected with indicated siRNAs 2 hours after UV. VCPi: VCP inhibitor (5 µM) was directly added after UV-C (4 J/m 2 ). (I) Immunoblot of chromatin fraction of indicated cell lines 1 hour after 12 J/m 2 UV-C or mock treatment. NAEi = 1 hour treatment with NEDDylation inhibitor (10 µM). SSRP1 is shown as loading control. (J) Immunoblot of chromatin fraction of HCT116 cells transfected with indicated siRNAs 1 hour after 12 J/m 2 UV-C or mock treatment. SSRP1 is shown as loading control.

Journal: bioRxiv

Article Title: Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability

doi: 10.1101/2021.05.11.443558

Figure Lengend Snippet: (A) Left panel: Schematic of the genomic locus of CSB and used strategy for generating the homozygous CSB-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for CSB -KI cell line. (B) Left panel: Schematic of the genomic locus of UVSSA and used strategy for generating the homozygous UVSSA-mScarletI-HA KI cell line. Half arrows indicate primer locations. Middle and right panel: Genotyping PCR and immunoblot for UVSSA -KI cell line. (C) Left panel: CSB mobility was determined by FRAP analysis of CSB-mScarletI after the indicated treatments. THZ1: 1 hour treatment (2 µM) before UV-C irradiation (4 J/m 2 ) or mock treatment. Right panel: Relative immobile fraction of CSB as determined by FRAP analysis. Plotted values represent mean ± SEM and are normalized to mock treated. n≥15 cells. (D) Same as C but for UVSSA-mScarletI. n≥10 cells. (E+F) FRAP analyses of CSB-mScarletI (E) or UVSSA-mScarletI (F) mobility after transfection with indicated siRNAs in individual graphs. Cells were mock treated (NT) or analyzed directly (UV) or 5 hours (5hr UV) after irradiation with 4 J/m 2 UV-C. (G) Relative fluorescence intensity of UVSSA in UVSSA -KI cells transfected with indicated siRNAs as determined by live-cell imaging. Plotted values represent mean ± SEM. n≥16 cells. (H) FRAP analysis of CSB in CSB -KI cells transfected with indicated siRNAs 2 hours after UV. VCPi: VCP inhibitor (5 µM) was directly added after UV-C (4 J/m 2 ). (I) Immunoblot of chromatin fraction of indicated cell lines 1 hour after 12 J/m 2 UV-C or mock treatment. NAEi = 1 hour treatment with NEDDylation inhibitor (10 µM). SSRP1 is shown as loading control. (J) Immunoblot of chromatin fraction of HCT116 cells transfected with indicated siRNAs 1 hour after 12 J/m 2 UV-C or mock treatment. SSRP1 is shown as loading control.

Article Snippet: Cell were treated for 1 hour with the following chemicals: Actinomycin D (Sigma, 1 µg/ml), Flavopiridol (Sigma, 1 µM), THZ1 (Xcessbio, 2 µM), Mitomycin C (Sigma, 10 µg/ml unless indicated differently), or potassium bromate (KBrO 3 , Sigma).

Techniques: Western Blot, Irradiation, Transfection, Fluorescence, Live Cell Imaging